French Firm Explores U.S. Regulatory Strategy For Blood-based Alzheimer’s Test
This article was originally published in The Gray Sheet
With a CE mark in hand, Exonhit is training its sights on the U.S. market. A 160-patient pilot study conducted through the Cleveland Clinic completed enrollment a few weeks ago.
You may also be interested in...
More people would be screened for health conditions ranging from diabetes to colorectal cancer to sleep apnea over the next decade under goals set out in HHS’ recent “Healthy People 2020” initiative.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.